Sensei Biotherapeutics (NASDAQ:SNSE) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Sensei Biotherapeutics (NASDAQ:SNSEFree Report) in a research note published on Wednesday,Benzinga reports. HC Wainwright currently has a $4.00 price objective on the stock.

Sensei Biotherapeutics Stock Performance

Shares of NASDAQ:SNSE opened at $0.53 on Wednesday. Sensei Biotherapeutics has a 52-week low of $0.38 and a 52-week high of $1.94. The firm has a market capitalization of $13.33 million, a P/E ratio of -0.45 and a beta of 0.17. The stock has a 50 day moving average price of $0.50 and a 200-day moving average price of $0.56.

Institutional Trading of Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. National Bank of Canada FI increased its holdings in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSEFree Report) by 355.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,575 shares of the company’s stock after acquiring an additional 35,575 shares during the period. National Bank of Canada FI owned approximately 0.18% of Sensei Biotherapeutics worth $27,000 at the end of the most recent reporting period. 10.50% of the stock is currently owned by institutional investors and hedge funds.

Sensei Biotherapeutics Company Profile

(Get Free Report)

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.

Further Reading

Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.